Abstract
Type 2 diabetes mellitus affects more than 400 million people around the world with a prospective increase in the number of patients of more than 640 million in 2040. The disease is characterized mainly by excess glucose in the blood due to irregular and insufficient secretion of insulin, and Lobeglitazone, a compound of the class of glitazones that functions as an insulin sensitizer in h…